As such, diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin’s lymphoma (NHL), was identified as a suitable target for CD47 blocking therapy based on its high SLAMF7 mRNA levels. This evidence concerns the gene SLAMF7 and non-Hodgkin lymphoma.